Buscar
Mostrando ítems 1-10 de 78
Translation of clinical problems in osteoarthritis into pathophysiological research goals
(BMJ, 2016-05-26)
[Abstract] Osteoarthritis (OA) accounts for more disability among the elderly than any other disease and is associated with an increased mortality rate. The prevalence in Europe will rise in the future since this continent ...
OARSI Guidelines for the Non-Surgical Management of Knee, Hip, and Polyarticular Osteoarthritis
(Elsevier, 2019-11)
[Abstract] Objective: To update and expand upon prior Osteoarthritis Research Society International (OARSI) guidelines by developing patient-focused treatment recommendations for individuals with Knee, Hip, and Polyarticular ...
Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib
(BMJ, 2015-01-14)
[Abstract] Objectives. To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain.
Methods. Double-blind ...
Amentadione from the Alga Cystoseira usneoides as a Novel Osteoarthritis Protective Agent in an Ex Vivo Co-Culture OA Model
(MDPI, 2020-12-07)
[Abstract] Osteoarthritis (OA) remains a prevalent chronic disease without effective prevention and treatment. Amentadione (YP), a meroditerpenoid purified from the alga Cystoseira usneoides, has demonstrated anti-inflammatory ...
Oleate prevents palmitate-induced mitochondrial dysfunction in chondrocytes
(Frontiers, 2021-06-15)
[Abstract] The association between obesity and osteoarthritis (OA) in joints not subjected to mechanical overload, together with the relationship between OA and metabolic syndrome, suggests that there are systemic factors ...
Subcutaneous Tanezumab for Osteoarthritis: Is the Early Improvement in Pain and Function Meaningful and Sustained?
(Wiley, 2021-03-16)
[Abstract] Background: To evaluate if early improvements in pain and function with subcuta-neous tanezumab are meaningful and sustained over 24 weeks.
Methods: Patients with moderate- to- severe osteoarthritis (hip or ...
Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period
(BMJ, 2020-03-31)
[Abstract] Objective. Tanezumab, a nerve growth factor inhibitor, was investigated for osteoarthritis (OA) of the hip or knee in a study with 24-week treatment and 24-week safety follow-up.
Methods. This double-blind, ...
Relationship Between Motion, Using the GaitSmartTM System, and Radiographic Knee Osteoarthritis: An Explorative Analysis in the IMI-APPROACH Cohort
(Oxford, 2020-12-25)
[Abstract] Objectives: To assess underlying domains measured by GaitSmartTMparameters and whether these are additional to established OA markers including patient reported outcome measures (PROMs) and radiographic parameters, ...
Wnt and RUNX2 mediate cartilage breakdown by osteoarthritis synovial fibroblast‐derived ADAMTS‐7 and ‐12
(Wiley, 2019-03-22)
[Abstract] Failure of therapeutic approaches for the treatment of osteoarthritis (OA) based on the inhibition of metalloproteinases, might be because of their constitutive expression in homeostasis, together with their ...
Mitochondrial activity is modulated by TNFα and IL-1β in normal human chondrocyte cells
(Elsevier, 2006-05-05)
[Abstract] Objective. Pro-inflammatory cytokines play an important role in osteoarthritis (OA). In osteoarthritic cartilage, chondrocytes exhibit an alteration in mitochondrial activity. This study analyzes the effect of ...